Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896142 | 0.93 | CNR1 (0.37) | CNR1NTRK1CNR2PDE10AMEN1 | |
| SCHEMBL4906357 | 0.93 | KDM4E (0.41) | KDM4ENTRK1CNR2MEN1KMT2A | |
| SCHEMBL4575789 | 0.89 | NTRK1 (0.39) | KDM4ECNR1NTRK1CNR2MEN1 | |
| SCHEMBL4907817 | 0.87 | CNR2 (0.40) | KDM4ECNR1CNR2PIK3CA | |
| SCHEMBL4906999 | 0.87 | KDM4E (0.45) | KDM4EMEN1KMT2A | |
| SCHEMBL4591218 | 0.87 | KDM4E (0.45) | KDM4EMEN1KMT2A | |
| SCHEMBL4575790 | 0.87 | KDM4E (0.45) | KDM4EMEN1KMT2A | |
| SCHEMBL4909302 | 0.85 | KDM4E (0.46) | KDM4EMEN1KMT2A | |
| SCHEMBL4895081 | 0.85 | NTRK1 (0.37) | KDM4ENTRK1MEN1KMT2AGRIN2B | |
| SCHEMBL4898690 | 0.85 | CNR2 (0.40) | KDM4ECNR1CNR2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | KDM4E 1139/4885CNR1 4694/4885NTRK1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.